Redeye provides a brief comment on Scandinavian ChemoTech's order intake for April, announced early in the morning yesterday. In short, it seems current momentum is even stronger than we had expected. We expect to increase our estimates and valuation in conjunction with the Q1 report, due on May 6.
LÄS MER
